Fig. 4From: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in ChinaCost-effectiveness acceptability curveBack to article page